EUVIMEDOpdag EUVIMED
FallberichtOpen access · CC BY-NC-ND 4.0

Neuroleptic malignant syndrome in Huntington disease

Antonio Funcis iD, Beatrice Ravera, Paola Zinzi, Marcella Solito, Martina Petracca, Paolo Calabresi, Anna Rita Bentivoglio

European Journal of Neurology · 2024

DOI: 10.1111/ene.16442 ↗

At a glance

Fallbericht in European Journal of Neurology, 2024. Written by Antonio Funcis and 6 co-authors. Institution: Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy. Major MEDLINE topics: Huntington Disease, Neuroleptic Malignant Syndrome. Cited 2 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Despite the wide use of dopamine receptor blocking agents (DRBAs) in Huntington disease (HD), neuroleptic malignant syndrome (NMS) is rarely described in this population. The aim of this study was to assess NMS prevalence in a large cohort of HD patients and explore the main associated risk factors.

Methods

In 2023, an HD patient was admitted to our neurology department due to NMS. Starting from the case description, we performed a narrative review of the literature of NMS cases in HD, reviewed data from the fifth dataset of the Enroll‐HD (a longitudinal, observational, global study of families with HD) study (PDS5) selecting HD patients treated with DRBAs and/or tetrabenazine (TBZ) who presented at least one of the core symptoms of NMS (rigidity and hyperthermia), and collected data to investigate prevalence of NMS and identify risk factors.

Results

In the Enroll‐HD PDS5 dataset, we identified 5108 of 11,569 HD patients who were undergoing DRBA and/or TBZ treatment. Only one patient, a Caucasian man of 46 years, undergoing clozapine and valproate treatment, had a registered diagnosis of NMS.

Conclusions

NMS in HD patients is seldom described. This could be due to an underestimation of this condition. There are no available objective NMS diagnostic criteria at present, and the existence of atypical forms of NMS further complicates diagnosis. Advanced disease stage, rigid–akinetic phenotype, abrupt therapy changes, polytherapy, and dehydration are key risk factors, most of which are preventable through awareness and caution in managing medications in the HD population.

Subjects

MeSH terms (MEDLINE)

Huntington DiseaseNeuroleptic Malignant SyndromeHumansMaleMiddle AgedAntipsychotic AgentsDopamine AntagonistsPrevalenceRisk FactorsTetrabenazine

Author keywords

Huntington diseasedopamineneuroleptic malignant syndromeneurolepticstetrabenazine

Substances

Antipsychotic AgentsDopamine AntagonistsTetrabenazine

Authors and institutions

  • Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy.
  • Institute of Neurology, Policlinic A. Gemelli Foundation, Rome, Italy.

ORCID profiles: Antonio Funcis

Cite

APA

Funcis, A., Ravera, B., Zinzi, P., Solito, M., Petracca, M., Calabresi, P., & Bentivoglio, A. R. (2024). Neuroleptic malignant syndrome in Huntington disease. European Journal of Neurology. https://doi.org/10.1111/ene.16442

Vancouver

Funcis A, Ravera B, Zinzi P, Solito M, Petracca M, Calabresi P, et al. Neuroleptic malignant syndrome in Huntington disease. European Journal of Neurology. 2024. doi:10.1111/ene.16442

BibTeX
@article{Funcis2024,
  author = {Funcis, Antonio and Ravera, Beatrice and Zinzi, Paola and Solito, Marcella and Petracca, Martina and Calabresi, Paolo and Bentivoglio, Anna Rita},
  title = {Neuroleptic malignant syndrome in Huntington disease},
  journal = {European Journal of Neurology},
  year = {2024},
  doi = {10.1111/ene.16442}
}
Start for free →